Molecular Oncology & Biomarker-Driven Surgical Strategy

Integrating Tumor Biology into Surgical Decision-Making

In complex gastrointestinal and hepatopancreatobiliary malignancies, operative decisions are shaped by both anatomy and biology. While resectability is defined radiographically, long-term oncologic outcome is frequently determined by tumor behavior, genomic profile, and systemic response.

This is particularly true in pancreatic and biliary cancers, where biologic heterogeneity and early micrometastatic risk demand disciplined sequencing and early systemic integration.

As a fellowship-trained robotic surgical oncologist and physician-scientist, Dr. Geoffrey W. Krampitz integrates imaging, pathology, biomarker data, and clinical trajectory into multidisciplinary strategy. The objective is not simply technical resection, but oncologic intervention aligned with disease biology.

Incomplete staging or molecular workup should never delay referral.

The information below reflects contemporary biomarker considerations relevant to surgical planning. Our office can facilitate additional testing, pathology review, or imaging coordination when appropriate.

Strategic Role of Molecular Profiling in HPB Malignancies

Molecular characterization increasingly informs the integration of systemic therapy within surgical planning — particularly in pancreatic and biliary malignancies, where early micrometastatic disease is common.

Biomarker data may influence:

  • Alignment of neoadjuvant systemic therapy in resectable and borderline resectable disease

  • Assessment of biologic response prior to operative intervention

  • Evaluation of conversion-to-resection potential in locally advanced presentations

  • Identification of actionable or targetable alterations

  • Eligibility for biomarker-driven clinical trials

  • Biologic risk assessment and postoperative surveillance planning

In contemporary HPB practice, sequencing is increasingly systemic-first and biology-informed. Molecular data helps determine not only whether a tumor can be removed, but when operative intervention is oncologically appropriate.

Biomarker Considerations by Disease Site

Pancreatic Ductal Adenocarcinoma (PDAC)

Given its aggressive biology and systemic recurrence risk, comprehensive molecular characterization is increasingly foundational to pancreatic cancer management.

Baseline Evaluation

  • Germline testing (including BRCA1/2, PALB2, and broader hereditary panels when indicated)

  • Somatic next-generation sequencing (tissue preferred; liquid biopsy when limited)

  • MSI/MMR status

Actionable Biology and Trial-Relevant Alterations

  • DNA damage repair pathway alterations (e.g., BRCA1/2, PALB2) may inform platinum sensitivity and maintenance strategies, including PARP inhibition in appropriate clinical contexts, and provide access to biomarker-driven trials.

  • MSI-high/MMR-deficient tumors, though uncommon, carry significant therapeutic implications.

  • Rare actionable fusions (e.g., NTRK) warrant identification despite low prevalence.

  • KRAS pathway biology is central to PDAC. Allele-specific inhibitors apply to select subsets, and broader KRAS-directed strategies remain under active clinical investigation within trial settings.

Relevance to Surgical Strategy

  • Refines neoadjuvant therapy selection in resectable and borderline resectable disease

  • Supports assessment of conversion candidacy in locally advanced presentations

  • Expands access to perioperative clinical trials

  • Provides biologic context when determining operative timing

Prospective and real-world data have underscored the clinical importance of molecular profiling in pancreatic cancer. Programs such as Know Your Tumor demonstrated improved outcomes among patients whose tumors were molecularly characterized and appropriately matched to targeted therapy compared with unmatched cohorts. While actionable alterations are not universal, these findings reinforce the importance of early sequencing to identify therapeutic and clinical trial opportunities when present.

Cholangiocarcinoma & Biliary Tract Malignancies

Biliary tract cancers demonstrate one of the highest rates of actionable genomic alterations among GI malignancies. Early comprehensive molecular profiling is generally appropriate.

Baseline Evaluation

  • Broad somatic NGS panel

  • MSI/MMR status

  • HER2 assessment in selected contexts

Commonly Actionable Alterations

  • FGFR2 fusions or rearrangements

  • IDH1 mutations

  • BRAF V600E

  • HER2 amplification/overexpression (subset)

  • Rare NTRK fusions

Relevance to Surgical Strategy

  • Influences systemic sequencing in advanced or borderline disease

  • May support downstaging or conversion strategies

  • Identifies candidates for targeted and biomarker-driven trials

  • Provides biologic context in recurrence risk assessment

Hepatocellular Carcinoma (HCC)

Management remains primarily guided by hepatic reserve, portal hypertension, and tumor burden. Molecular profiling is selectively considered in atypical cases or trial contexts. Surgical decision-making remains fundamentally anchored in liver function and oncologic distribution.

Colorectal Cancer (CRC)

Baseline Evaluation

  • MSI/MMR

  • KRAS/NRAS

  • BRAF

  • HER2 (selected contexts)

Emerging Application

  • Circulating tumor DNA for minimal residual disease assessment in selected postoperative settings

Molecular data informs systemic sequencing and may influence timing of hepatic or oligometastatic resection.

Gastric, GEJ, and Esophageal Adenocarcinoma

Baseline Evaluation

  • HER2

  • MSI/MMR

  • PD-L1 (CPS)

  • EBV in selected gastric cancers

Molecular findings inform perioperative systemic strategy and trial alignment.

Pancreatic and Gastrointestinal Neuroendocrine Tumors

Core assessment remains centered on grade, Ki-67 index, differentiation, and disease distribution. Selective germline or somatic testing may be appropriate in higher-grade or atypical presentations.

Practical Testing Considerations

Adequate tumor cellularity is essential for reliable sequencing. Core biopsy or surgical specimens should include specimen source documentation.

Liquid biopsy may be useful when tissue is limited; negative results do not exclude actionable alterations.

Common barriers — limited tissue, external imaging transfer, delayed germline testing, or insurance authorization — should not postpone multidisciplinary evaluation.

Clinical Trial and Translational Alignment

Molecular profiling frequently serves as a gateway to clinical trial eligibility and biomarker-directed therapeutic strategy. In pancreatic and biliary malignancies in particular, biomarker-directed strategies — including DNA damage response–targeted approaches, KRAS pathway investigations, and FGFR- or IDH-directed therapies — may influence treatment sequencing.

When appropriate, molecular findings are integrated into perioperative planning and multidisciplinary decision-making.

Conclusion

Pancreatic and biliary malignancies demand disciplined integration of systemic therapy, operative judgment, and tumor biology. Molecular characterization is increasingly foundational to contemporary oncologic strategy in HPB malignancies.

Through coordinated multidisciplinary evaluation and careful sequencing, biologic insight can be translated into more informed operative decision-making. The objective is not merely technical resection, but oncologic strategy aligned with disease biology.

Early referral allows molecular data to be incorporated within a structured surgical framework. Even when testing is incomplete, multidisciplinary review can clarify next steps and streamline further evaluation.

Physician Communication

For case discussion or coordination of molecular workup:

Office: (650) 652-8787
Fax: (650) 652-8770
Email (non-urgent; no PHI): geoffrey.krampitz@sutterhealth.org

Referral logistics are available on the For Physicians page.